RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA (R/R PTCL)

Clinical trials for RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA (R/R PTCL) explained in plain language.

Never miss a new study

Get alerted when new RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA (R/R PTCL) trials appear

Sign up with your email to follow new studies for RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA (R/R PTCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New pill tested for aggressive blood cancer after other treatments fail

Disease control Recruiting now

This study is testing an oral drug called HH2853 for people with a type of blood cancer called peripheral T-cell lymphoma that has come back or hasn't responded to previous treatments. The goal is to find a safe and effective dose and to see if the drug can help control the cance…

Matched conditions: RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA (R/R PTCL)

Phase: PHASE1, PHASE2 • Sponsor: Haihe Biopharma Co., Ltd. • Aim: Disease control

Last updated Mar 30, 2026 14:34 UTC

RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA (R/R PTCL)

Get alerted when new RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA (R/R PTCL) trials appear

New pill tested for aggressive blood cancer after other treatments fail